EXPERIENCE OF USING TB TEST KIT FOR THE RAPID DRUG SUSCEPTIBILITY TESTING OF M. TUBERCULOSIS
The results of the comparative testing of the susceptibility of M. tuberculosis clinical strains to isoniazid, streptomycin, rifampicin and ethambutol using the TB test kit, developed in SCRAMB, (Obolensk) and the absolute concentrations method; the TB test kit and the BACTEC MGIT 960 automated system are presented in the study. A total of 629 and 220 strains, respectively, were tested. A high degree of agreement of the results was shown: 89.1-98.6% for isoniazid, 96.2-98.0% for rifampicin, 91.5-98.2% for streptomycin and 89.1-95.9% for ethambutol. The smallest number of discrepancies in the results was obtained when comparing the TB test kit and BACTEC MGIT 960. The discrepant results analysis was performed by the proportion method, PCR sequencing, or re-testing on new lots of the TB test kit and Lowenstein-Jensen medium with anti-tuberculosis drugs, after which the sensitivity, the specificity and the efficiency of the TB test kit have exceeded 95 % for all anti-tuberculosis drugs. The turnaround time with the TB test kit (median 9.25-9.9 days, ranged from 8 to13 days) was significantly shorter than that with the absolute concentration method (median 21-23 days, ranged from 20 to 28 days) and is commensurate with the turnaround time with BACTEC MGIT 960 (average 7.2 days, ranged from 5 to 12 days). The TB test kit is easy to use, does not require expensive equipment and special staff training.
About the authorsDomotenko L.V.
Angeby K. A., Klintz L., Hoffner S. E. Rapid and Inexpensive Drug Susceptibility Testing of Mycobacterium tuberculosis with a Nitrate Reductase Assay. J. Clin. Microbiol. 2002; 40 (2): 553-5.
Affolabi D., Odoun M., Martin A., Palomino J.C., Anagonou S., Porataels F. Evaluation of Direct detection of Mycobacterium tuberculosis Rifampin Resistance by Nitrate Reductase Assay Applied to Sputum Samples in Cotonou, Benin. J. Clin. Microbiol. 2007; 45: 2123-5.
Kohli A., Bashir G., Fatima, A., Jan A., Wani N., & Ahmad J. Rapid drug-susceptibility testing of Mycobacterium tuberculosis clinical isolates to first-line antitubercular drugs by nitrate reductase assay: A comparison with proportion method. International Journal of Mycobacteriology. 2016; 5(4): 469-74.
Toman K. Sensitivity, specificity and predictive value of diagnostic tests. Bull. Int. Union Tuberc. 1981; 56: 18-28.
Kent P., Kubica G. Public Health Mycobacteriology. A Guide for the level III Laboratory.US DHHS: Center for Diseases Control, Atlanta; 1985.
Sanger F. DNA Sequencing with Chain-Terminating Inhibitors. Proc. Natl. Acad. Sci. USA. 1977; 74: 5463-5.
Macrousov I., Otten T., Vyshnevskiy B., Narvskaya O. Detection of embB 306 Mutations in Ethambutol-Susceptible Clinical Isolates of Mycobacterium tuberculosis from Northwestern Russia: Implications for Genotypic Resistance Testing. J. Clin. Microbiol. 2002; 40; 3810-3.
Walker T.M., Kohl T.A., Omar S.V., et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect. Dis. 2015; 15: 1193-1202.
Schön T., Miotto P., Köser C.U., Viveiros M., Böttger E., Cambau E. Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives. Clin. Microbiol. Infect. 2017; 23: 154-60.
Horne D.J., Pinto L. M., Arentz M., Lin S.-Y.G., Desmond E., Flores L.L. et al. Diagnostic Accuracy and Reproducibility of WHO-Endorsed Phenotypic Drug Susceptibility Testing Methods for First-Line and Second-Line Antituberculosis Drugs. J. Clin. Microbiol. 2013; 51: p. 393-401.
High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. Geneva: World Health Organization; 2014. Available at: http://www.who.int/tb/publications/tpp_report/en/).
- Refbacks are not listed
Контент доступен под лицензией Creative Commons Attribution 3.0 License.